Dr. Dolinar on WFAS AM Talk Radio

November 21, 2013

Dr. Dolinar discusses biosimilars with Seth Ginsberg of the Global Healthy Living Foundation on WFAS AM 1230 talk radio, Greater NYC. Listen here.

Read More


Dr. Dolinar Keynote at AfPA Working Group on Biologics, Chicago

November 15, 2013

The Alliance for Patient Access (AfPA) held their National Physicians Biologics Working Group Meeting on November 15-16 in Chicago, IL where Dr. Dolinar gave the keynote address to attending physicians. In his address, Dr. Dolinar discussed the current state of biosimilars and explained the disconnect between the science and potential policies and how they will impact […]

Read More


Dr. Dolinar Addresses State Legislators at NALEO Summit on Health

November 6, 2013

On October 26, Dr. Richard Dolinar served as the keynote luncheon speaker at the National Association of Latino Elected and Appointed Officials (NALEO) Legislative Summit on Health in Las Vegas. Dr. Dolinar discussed the science and policy issues surrounding biosimilar provisions of the Patient Protection and Affordable Care Act with state legislators from across the […]

Read More


ASBM Executive Director Featured in Globe & Mail Video Series on Biosimilars

October 28, 2013

The Alliance for Safe Biologic Medicines (ASBM) executive director, Michael Reilly, was featured in a Globe & Mail video series on biosimilars. Mr. Reilly provides a global perspective on biosimilars, with a focus on why manufacturing matters. Globe & Mail is the national newspaper for Canada and this new online series will provide viewers with […]

Read More


Andrew Spiegel Op-Ed Featured in Pittsburgh Post-Gazette

October 28, 2013

Allow ‘biosimilars’ in Pennsylvania These medications will improve health and cut costs The Pennsylvania Legislature is considering a measure to make sure patients have safe access to an important new class of drugs called “biosimilars.” If the bill passes, Pennsylvania will follow North Dakota, Oregon, Utah and Virginia in taking this critical legislative action. “Biosimilars” […]

Read More


ASBM Presents at WHO Meeting on Naming in Geneva

October 22, 2013

ASBM Presents at WHO Meeting on Naming in Geneva Calls for Distinct Non-Proprietary Names to Ensure Patient Safety Geneva, Switzerland – The Alliance for Safe Biologic Medicines (ASBM) today presented at the World Health Organization’s (WHO) 57th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. During his presentation, ASBM Chairman, Richard […]

Read More


IAPO Mexico City Meeting Includes Discussion on Biosimilars

September 23, 2013

On September 23rd, in Mexico City, the International Alliance of Patients’ Organizations (IAPO) hosted a discussion on biosimilars at their Latin American Multi-Stakeholder Seminar.  The meeting was attended by patient and interest groups from the region as well as ASBM Executive Director, Michael Reilly, and Global Colon Cancer Association (GCCA) Co-Executive Director, Andy Spiegel. The discussion […]

Read More


The Alliance for Safe Biologic Medicines Statement on the Need for Unique Names for All Biologic Medicines

September 20, 2013

WASHINGTON, DC – Alliance for Safe Biologic Medicines (ASBM) chairman, Richard Dolinar M.D., added a physician’s perspective to the ongoing discussion around the naming of biologic medicines, including biosimilars. “Biologics are highly sensitive to the manufacturing process and their environment; slight differences can have unexpected results,” stated Dolinar. “As a physician, patient safety is paramount. […]

Read More


American Academy of Dermatology Updates Biosimilar Statement

August 15, 2013

This month, the AADA’s Board of Directors approved an updated version of their position statement on biosimilars.  The AADA specifically adds new language to clarify physician notification by pharmacists. Read full statement here.

Read More


Article in GEN Insight & Intelligence: Latest Biosimilar Guidance Raises More Questions. Quick FDA action just as unlikely as last year, when agency issued original policy advice.

July 9, 2013

Testifying before Congress in April, FDA Commissioner Margaret A. Hamburg, M.D., sought to reassure lawmakers: “We are developing a science-based process for bringing safe and effective biosimilar and interchangeable products to market, which should increase competition and create substantial savings for patients, healthcare providers, and insurers.” More than a year after issuing three draft guidances […]

Read More